Scott Hutton Email & Phone Number

Louisville, Colorado, Us

Business growth highlights1H 2024• $32.7 million in total Revenue• 56% total Revenue growth over 1H 2023• 46% Lung Diagnostic test volume growth over 1H 2023• 51% Lung Diagnostic revenue growth over 1H 2023• 189% Biopharma Services revenue growth over 1H 2023• 79% Gross Profit Margin• 44% improvement in Adj EBITDA over 1H 20232023• Total Revenue = $49.1 million (49% growth over 2022)• 65% Lung Diagnostic test volume growth over 2022• 55% Lung Diagnostic revenue growth over 2022Company and Team• 5 Medicare covered tests in Lung Disease Diagnostics• >650,000 tests results delivered all-time• Initial Public Offering (IPO) in October 2020Advancements in Science, Research, and IP• >300 publications, presentations, and abstracts including the ORACLE clinical utility study (7/23)• >65 Biopharmaceutical companies partnering for research and development services• >8 technology platforms for research use• ~122 issued patents and 22 trademarks covering the US and certain global territories• Multi-omic (genomic + proteomic) offering for both clinical and research use• Major partnerships and agreements with Academic researchers, Research Consortiums, Technology providers, and Software developersCulture & Leadership achievements• Dedicated to maintaining and improving diversity of our teammates – team comprised of >50% women• Committed to building a workplace culture that is engaging and fulfilling for all team membersAwards & Recognition• Inc. Magazine’s 2024 Best Workplaces• Newsweek Top Digital Healthcare Companies of 2024• Healthcare Technology Report’s Power 500 Healthcare Technology Companies of 2023• Healthcare Technology Report’s Top 100 Healthcare Technology Companies of 2022• Life Sciences Review Magazine’s Top Proteomic Solutions Company of 2022

Louisville, Colorado, Us

Louisville, Colorado, Us

Reported directly to the Founder & CEO and interacted with the Biodesix Board of Directors, Observers, Investors, Bankers and Analyst. Recruited and hired to be the CEO-in-waiting. Responsible for leadership of the Biodesix business and teams (Boulder, CO, USA; De Soto, KS, USA; Seattle, WA, USA; Steamboat Springs, CO, USA) consisting of 150 teammates. • Launched the Nodify XL2 "Rule-Out" Proteomic Test in September 2019.• Led strategic and transformational shift from lung cancer treatment/therapeutic guidance focus to broader lung cancer continuum of care (to include diagnosis) focus.• Colorado BioScience Association (CBSA) Company of the Year winner in 2019 and finalist in 2018.• Acquired and integrated two businesses, teams, labs, and tests/products. July 2018, Seattle, WA–based Integrated Diagnostics, Inc. (Indi) and the Xpresys Lung 2 (Nodify XL2) proteomic test which offers a noninvasive means of ruling out cancer for patients with suspicious lung nodules; and October 2019, De Soto, KS–based Oncimmune USA (ONC) and the EarlyCDT-Lung (Nodify CDT) proteomic test which offers a noninvasive means of identifying malignant lung nodules.• Proprietary Blood Specimen Collection Device (BCD) US Patent secured in 2019 and NY State-Clinical Lab Evaluation Program (CLEP) approval received in 2018.• Enrolled 3,000+ patients into the VeriStrat INSIGHT observational study• Appointed Co-Chief Medical Officers (CMO), Dr. James Jett and Dr. Steven Springmeyer

Washington, Dc, Us

Colorado Springs, Colorado, Us

Executive Officer reporting directly to the President & CEO and interacting with the SPNC Board of Directors, Investors and Analyst. Recruited and hired to be the CEO-in-waiting. Responsible for leadership of the $181.6M (2016) Vascular Intervention (VI) business and teams (Broomfield, CO, USA; Colorado Springs, CO, USA; Fremont, CA, USA; Maple Grove, MN, USA) consisting of 750+ teammates with an expense budget of $84.2M. • Achieved >10% quarterly growth (11% (Q1), and 11% (Q2)) over prior year• Generated $46.4M (Q1), $51.0M (Q2)• Achieved 24% Net Promoter Score (NPS) for FY17 vs. 18% prior year (FY16)• Achieved 82% Willingness to Recommend (WTR) for FY17 vs. 65% prior year (FY16)• Achieved >20% Vitality Index• Participated in the sale of Spectranetics Corp to Royal Philips Image Guided Therapy (IGT) Business Group for $2.2B. Led post-acquisition integration on the Spectranetics Vascular Interventions (VI) side.• Launched two products (Stellarex Drug-Coated 0.035” OTW Angioplasty Balloon (DCB) in July, Turbo-Power 6Fr Laser Atherectomy Catheter in February)• ColoradoBiz Magazine “Top Company” in Manufacturing (2017), BrainShark Sharkie Sales Enablement Program of the Year (2017)• Fourteen member VI leadership team (eight direct reports & six dotted line reports) located in four locations

Minneapolis, Mn, Us

Reported directly to the President of the Brain Therapies division. Responsible for the transition from Surgical Technologies into the newly created Brain Therapies division. Responsible for the leadership of four different businesses and sites (Midas Rex in Ft. Worth, TX; PS Medical in Goleta, CA; BreakAway Imaging in Littleton, MA; Surgical Navigation Technologies in Louisville, CO) with 2,400+ employees focused on transforming the way the world treats patients with brain and spine disorders. Created and implemented the unified and comprehensive Neurosurgery vision, 5-year transformational strategy and org structure.Achieved 9.9% (FY17 YTD) annual revenue growth.Positioned to generate >$1.0B in annual revenue in FY17.Exceed budget two out of two quartersResponsible for 2 surgical robotics business development transactions (1 lead share/distribution agreement for Spine and 1 structured acquisition for Cranial).Launched four products (StrataMR, Cranial Perforator, Navigated Drill, MazorX Spine Robot) with StealthStation S8 awaiting FDA approval.Led strategic and transformational shift from surgical instruments, enabling technologies and services to therapies and integrated procedural solutions (imaging + surgical navigation + robotics + lasers + powered instruments + monitoring).Initiated STELAR (STEreotactic Laser Ablation Registry) Neuro Tumor registry for indication expansion of Visualase MRI-Guided Laser Ablation Technology.Thirteen member leadership team (seven direct reports and six dotted line reports) located in three locations.

Minneapolis, Mn, Us

Reported directly to President of Surgical Technologies division. Responsible for integration & leadership of six different businesses, teams, & sites (Midas Rex in Ft. Worth, TX, USA; PS Medical in Goleta, CA, USA; Visualase in Houston, TX, USA; BreakAway Imaging in Littleton, MA, USA, Surgical Navigation Technologies in Louisville, CO, USA; Odin Medical in Yokneam, Israel) w 2,400+ employees to create the new Neurosurgery business unit focused on transforming the way the world treats patients w brain & spine disorders. Created & implemented the unified & comprehensive Neurosurgery vision, 5-year transformational strategy & org structure.Achieved >6.5% annual revenue growth each fiscal year (12.8% (FY13), 9.3% (FY14), 6.7% (FY15), 9.2% (FY16)Generated $773.1M (FY13), $844.5M (FY14), $889.0M (FY15), and $950.6M (FY16) in annual revenueAchieved 41% (FY13), 57% (FY14), 57% (FY15), and 57% (FY16) Net Promoter Score (NPS)Exceed budget seventeen out of twenty quartersResponsible for 1 acquisition, 3 equity investments, 2 license agreements & 4 distribution agreementsLaunched twelve products (Cranial 2.25/2.2.7/3.0 SW, Spine 2.1 SW, O-arm Cranial EC3D SW, Navigated Osteotomes & Interbody, SonoNav SW, MicroSaws, NIM Eclipse GUI, O-arm O2, ClearView, Visualase Ti Bone Anchor & Enhanced Visualization).Led strategic & transformational shift from surgical instruments, enabling technologies & services to therapies & integrated procedural solutions (imaging+surgical navigation+robotics+lasers+powered instruments+monitoring).Medtronic Neurosurgery Strive Award recipient.CBSA Company of the Year finalist in 2013 & Chairman's Award in 2015.Initiated SLATE (Stereotactic Laser Ablation for Temporal Lobe Epilepsy) IDE study for indication expansion of Visualase MRI-Guided Laser Ablation Technology.Executive sponsor for Medtronic Emerging Leader Program (4/12-4/15).Thirteen member leadership team (seven direct reports and six dotted line reports) located in three locations.

Minneapolis, Mn, Us

Reported directly to the President of the Surgical Technologies division. Responsible for leading and managing the Navigation leadership team, strategic plan implementation and tactics for the remainder of FY12 while maintaining prior Global Marketing responsibilities.Achieved 14.0% annual revenue growth and generated $269.2M in FY12 (exceed plan by $15.7M)Achieved 46% Net Promoter Score (NPS) for FY12.Launched four products (Cranial 2.2 SW, AxiEM-only StealthStation S7, Navigation Optical Spheres, FrameLink 5.4 SW).Twelve member leadership team (six direct reports and six dotted line reports) all located in one location.

Minneapolis, Mn, Us

Reported directly to the Vice President and General Manager of the Navigation business unit. Responsible for all Global Surgical Navigation and Intra-Operative Imaging technologies and services. Led a team of thrity-one marketing professionals located in two locations. Restructured and reorganized the team to better meet the global commercial marketing needs of the business and team.Achieved >11.0% annual revenue growth each fiscal year (18.4% (FY09), 11.0% (FY10), 14.6% (FY11))Achieved 26% Net Promoter Score (NPS) for FY11 (initial measurement).Launched twelve products (Cranial 2.0/2.1 SW, Spine 1.7/2.0 SW, Ortho Hip/Knee SW, PoleStar N30, Universal NavLock, Navigated Pak Needle, StealthViz SW, Skull Base SW, O-arm 3.1 SW).Medtronic Wallin Leadership Award recipient (6/11) for strong and effective leadership and commitment to developing talent and future leaders.Introduced and implemented Customer Satisfaction (CSAT) and Net Promoter Score (NPS) measurements and created a dedicated Survey facilitator position.Created a dedicated Services Marketing role.Crafted and implemented a social media marketing strategy and campaign.

Minneapolis, Mn, Us

Reported directly to the Vice President of Finance. Responsible for the assessment of business strategies and the evaluation of inorganic business development opportunities including: technology licenses, consulting and development arrangements, distribution agreements, mergers and acquisitions, strategic alliances, joint ventures and minority investments for the Medtronic Spinal and Biologics division.Completed fourteen intellectual property transactions, three development/license/supply agreements, two equity investments, one acquisition and one divestiture.

Minneapolis, Mn, Us

Reported directly to the Vice President and General Manager of the Spinal division. Responsible for all Intradiscal and Tumor/Trauma products. Led a team of twelve marketing professionals.Generated $366.6M in annual revenue with 5.2% growth in FY07 (first $100M+ Interbody device - Capstone).Launched four products (Crescent VBS, Scissor Jack, Posterior Microscope Instrument Set, Vantage Plate).Submitted patent application to the USPTO - Implants and Related Devices for Monitoring Bony Fusion, filed 11/06; published 7/08 (#20080177387).

Minneapolis, Mn, Us

Reported directly to the Group Director of the Spinal division Extradiscal product portfolio. Responsible for all TSRH brand products. Led a team of five marketing professionals.Generated $121.5M in annual revenue in FY05 and $115.6M in annual revenue in FY06.Launched two products (TSRH 3D plus MPA, TSRH SiLo).

Minneapolis, Mn, Us

Reported directly to the Director of the Spinal division Thoracolumbar product portfolio. Responsible for Trauma products (FY04) and Deformity products (FY03). Led team of three marketing professionals.Generated $58.8M with 68.6% growth (FY03) and $46.3M with 52.0% growth (FY04).Launched three products (X10 Crosslink Plate, Colorado II Sacral Plate, MSD Wire) in FY03 and one product (Vantage Plate) in FY04.

Minneapolis, Mn, Us

Reported directly to the Director of the Spinal division Thoracolumbar TSRH brand portfolio of products.Generated $69.9M in annual revenue with 9.8% growth in FY02.

Houston, Tx, Us

Denver, Us

Distributor for DePuy Orthopaedics, Biomet Orthopedics, Stackhouse and Orthosonics.

FY97 - National Sales Manager of the YearFY97 - First Sales Manager to exceed $3M in annual sales with 35% growth

Beloit, Wi, Us